UPDATE 2-CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis

1

(Adds analyst comment, share moves, and background in paragraphs 3, 8-11) By Rajasik Mukherjee Oct 5 (Reuters) – Australia's CSL said on Monday it had entered into an agreement with Swiss drugmaker

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)